Anixa Biosciences is a biotechnology company. Co.'s vaccine programs include: the development of a preventative vaccine against triple negative breast cancer and other forms of breast cancer; and the development of a preventative vaccine against ovarian cancer. Co.'s therapeutics programs include: the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell technology, initially focused on treating ovarian cancer, which is being developed at its subsidiary, Certainty Therapeutics, Inc.; and the development of anti-viral drug candidates for the treatment of Coronavirus disease 2019 focused on inhibiting certain protein functions of the virus. The ANIX YTD return is shown above.
The YTD Return on the ANIX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ANIX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANIX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|